• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

This New Report Provides an In-Depth Discussion of the Application of Biomarkers in Developing Novel Targeted Cancer Therapeutics

Posted on: Friday, 12 October 2007, 12:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c71358) has announced the addition of Biomarker Technology Platforms for Cancer Diagnoses and Therapies to their offering.

Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics has begun to answer these questions. Protein biomarkers are also useful. The purpose of this report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer.

Content Outline:

1. Overview

2. Introduction to Cancer Biology and the Diagnostic Industry

3. Market Analysis of the Cancer Biomarkers Space

4. Major Clinical Applications of Cancer Biomarkers

5. Breast Cancer

6. Ovarian Cancer

7. Prostate Cancer

8. Bladder Cancer

9. Colorectal Cancer

10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing

11. Leukemia Biomarkers

12. Lung Cancer

13. Enabling Technologies for Oncology Biomarker Discovery

14. Biomarker Tests Co-developed with Cancer Therapeutics as Companion Diagnostics

15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends

16. Cancer Biomarker Testing Sector and Company Analysis

17. Business Trends in the Industry

18. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms

Appendixes

Glossary

Index Of Figures

Index Of Tables

Companies Mentioned:

-- Abbott Diagnostics

-- Affymetrix, Inc

-- Agendia

-- Agendia BV

-- Agensys, Inc

-- Almac Group

-- AMDL, Inc

-- Arcturus Bioscience, Inc

-- Aureon Biosciences Corporation

-- Bayer Diagnostics Corporation

-- Beckman Coulter, Inc

-- Biocode SA

-- BioCurex, Inc

-- Biomarker Technologies

-- Biomedical Diagnostics LLC

-- Biomerica

-- bioMérieux

-- Biomira, Inc

-- Biomoda

-- BioModa, Inc

-- Bruker Daltonics

-- Byk Gulden

-- Cangen Biotechnologies, Inc

-- Caprion Proteomics

-- Celera Diagnostics

-- Cepheid

-- Ciphergen Biosystems, Inc

-- Clarient

-- Clarient, Inc

-- Claros Diagnostics

-- Clinical Data, Inc: PGxHealth and Cogenics

-- Correlogic Systems, Inc

-- Cytogen Corporation

-- Cytyc Corporation

-- Dako Cytomation

-- diaDexus LLC

-- Diagnocure (ImmunoCyt&8482;)

-- DiagnoCure, Inc

-- Diagnostic Products Corporation

-- Diagnostic Systems Laboratories, Inc

-- Digene Corporation

-- DRG International, Inc

-- DxS Ltd

-- EDP Biotech Corporation

-- Eisai Co, Ltd

-- Epigenomics

-- Exact Sciences Corporation

-- Exagen Diagnostics

-- Gene Logic, Inc

-- Genesis Genomics, Inc

-- Genomic Health

-- Gen-Probe, Inc

-- Health Discovery Corporation

-- Ikonisys, Inc

-- Immunicon Corporation

-- Immunomedics, Inc

-- Incyte Pharmaceuticals, Inc

-- InterGenetics®

-- Ipsogen

-- LabCorp

-- Matritech, Inc

-- Miraculins

-- Mitsubishi Kagaku Medical

-- Molecular Diagnostics, Inc (CytoCore)

-- Myriad Genetics, Inc

-- NimbleGen, Systems

-- Northwest Biotherapeutics, Inc

-- Oncotech, Inc

-- Orion Genomics

-- Oxford Genome Sciences

-- Panacea Pharmaceuticals, Inc

-- Phenomenone Discoveries

-- Polymedco, Inc

-- Power3 Medical Products

-- Proteome Systems Ltd

-- Qiagen NV

-- Sanko Junyaku Co, Ltd

-- SensiGen LLC

-- SuperArray Bioscience Corporation

-- Third Wave Technologies, Inc

-- Tosoh Medics

-- TriPath Imaging, Inc

-- Upstream Biosciences, Inc

-- Ventana Medical Systems, Inc

-- Veridex

-- Veridex LLC

-- Vysis

For more information visit http://www.researchandmarkets.com/reports/c71358.

Source: Business Wire

More News in this Category